Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. has demonstrated a promising trajectory in its clinical trials, with positive data emerging from both its Phase 2a study for colorectal cancer treatment and its Phase 2 study addressing post-COVID conditions using Ampligen. The consistent flow of encouraging results indicates strong potential catalysts for the company's stock as it continues to validate the efficacy of its flagship therapeutics in addressing unmet medical needs. Given this positive data trend, AIM ImmunoTech's focus on innovative immunotherapy solutions positions it favorably within the biotechnology sector, suggesting a robust outlook ahead.

Bears say

AIM ImmunoTech reported a net loss of $3.3 million with an earnings per share (EPS) of $(1.57), significantly exceeding expectations and indicating weaker financial performance than earlier estimates. Additionally, the company faces numerous risks including liquidity challenges, potential failures in clinical trials, and hurdles in obtaining regulatory approvals, all of which could impact its future viability and stock performance. The presence of these risks, coupled with the company's ongoing financial losses, contributes to a negative outlook on AIM ImmunoTech’s stock.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.